LL-37 Pre-Research Checklist: What to Verify Before You Order

Before an LL-37 order is placed, six items should be settled in writing: a batch-specific certificate of analysis you can view before you buy, identity confirmation by mass spectrometry sitting alongside the HPLC purity figure, contaminant panels appropriate to a highly cationic peptide, documented storage and shipping conditions, net peptide content rather than gross fill weight alone, and commercial terms — pricing, minimums, lead time, reorder path — stated plainly instead of negotiated case by case. LL-37 is a research compound. Nothing here concerns human use, and nothing here is legal advice.

For a wholesale buyer the checklist does double duty. You are not only qualifying material for your own shelves; you are inheriting a documentation trail that your customers will eventually ask to see. Whatever your supplier can or cannot produce becomes, in practice, what you can or cannot produce. That is why the verification work belongs at the front of the transaction, not after a pallet has already been received.

Why this particular peptide punishes sloppy sourcing

LL-37 is the C-terminal fragment of human cathelicidin (hCAP-18), a 37-residue sequence that is strongly cationic and amphipathic and that adopts helical structure under certain solution conditions. Research literature has examined it in the context of innate immune signaling, antimicrobial and biofilm interaction studies, and epithelial cell-signaling work. Studies report that its behavior in vitro is unusually condition-dependent — ionic strength, pH, the presence of serum proteins, and even the vessel material can shift observed activity.

That sensitivity has a direct procurement consequence. Two vials that both advertise high purity can behave differently if one carries more residual counterion from the purification step, more bound water, or a higher endotoxin burden. Cationic peptides are also known to adsorb to plastic and glass surfaces, which means material can be effectively lost before a single measurement is taken. None of those variables appear in a single purity percentage on a product page. A buyer who compares only that number is comparing the least discriminating figure available.

The practical read: for a compound like this, documentation is not bureaucracy. It is the variable set. A supplier that treats batch data as a courtesy rather than a deliverable is asking you to absorb risk you cannot quantify.

The document set that should exist before money moves

Ask for the full package up front and note how quickly it arrives. The set worth insisting on includes a batch-specific certificate of analysis tied to the exact lot you will receive, the underlying HPLC chromatogram rather than a transcribed number, mass spectrometry confirming molecular weight, a statement of peptide content versus gross fill weight, water content, and — depending on the assay work involved — endotoxin or bioburden data. Heavy metals and residual solvent panels round out the picture for anyone building a standardized incoming-inspection process.

Two industry practices deserve scrutiny. The first is charging for a COA, or releasing it only after purchase. If test data is a paid add-on, the pricing structure is telling you the testing is optional to the seller. The second is a COA with no lot number, no date, and no laboratory attribution — a document that cannot be tied to the vial in your hand is decorative. Publicly verifiable results, which a buyer can pull up independently rather than request by email, remove the question entirely.

Also ask what happens between lots. Consistency across reorders matters more to a wholesale operation than the performance of a single flagship batch, because your customers will reorder and will notice drift.

Reading a certificate of analysis line by line

The last row decides the value of every row above it. Traceability is what converts a test result into evidence.

The half of the checklist that happens on your side

Supplier vetting is only one column. The other is what your own operation does on receipt, and it should be written down before the first shipment rather than improvised after it.

Define a receiving procedure: who inspects, what is checked against the packing list, how the lot number on the vial is matched to the COA on file, and where that record is stored. Confirm the storage conditions stated on the supplier's documentation and make sure you have the capacity to meet them before ordering at volume — cold storage that is adequate for a trial order may not be adequate for a tier purchase. Lyophilized material should be inspected for appearance and cake integrity, and anything that arrives compromised should be documented photographically at the moment of receipt, not a week later when a claim is being argued.

Build in handling practices that respect the chemistry. Because cationic peptides are prone to surface adsorption and to degradation across repeated freeze-thaw cycles, research operations commonly plan aliquoting and container selection deliberately rather than as an afterthought. Keep research-use-only labeling intact and keep research inventory physically and administratively separate from anything customer-facing in your business. Retain documentation for a defined period; deciding the retention window in advance is far easier than reconstructing a paper trail under pressure.

Supplier questions that have nothing to do with chemistry

A compound can pass every analytical check and still be a bad sourcing decision if the commercial relationship behind it is opaque. Work through these before committing:

• Is pricing published or quote-only? Quote-only pricing is not automatically a red flag, but it makes cost modeling impossible and tends to mean the same product carries different prices for different buyers. Tiered structures you can see let you plan a reorder cadence.
• How are minimums defined? Per SKU, per order, or per month are three very different commitments. A per-SKU minimum forces inventory concentration; a per-order minimum lets you diversify your catalog while still qualifying.
• Where does fulfillment originate, and what is the stated lead time? Domestic fulfillment shortens the gap between reorder and shelf, and it removes customs variables from your planning.
• What is the process when a shipment is short, damaged, or delayed? Ask for the policy in writing. The answer you get before you are a customer is the most honest one you will hear.
• Who is your point of contact at volume? Ticket queues and named account contacts produce different outcomes when a reorder is time-sensitive.
• What does the application process involve? A supplier that verifies who its wholesale buyers are is applying the same scrutiny to you that you are applying to it. That is a feature.

The questions that belong with your attorney, not your supplier

This section is informational and is not legal advice. Licensing, labeling, and resale rules for research compounds vary by jurisdiction and by business model, and no supplier — including Real Peptides — can resolve them for you.

The productive approach is to bring your counsel a list of questions rather than a conclusion. Useful ones: What business licensing does my entity type need to purchase and resell research-use-only materials in the jurisdictions where I operate? What labeling and record-keeping obligations attach to my role in the chain? How should my marketing be constrained so that nothing I publish implies a use my products are not offered for? Does my professional or general liability coverage contemplate this category at all? If my business holds a professional license, what does my state board expect of me here, and should I request written guidance before proceeding?

Treat every one of those as open until your attorney or your state board answers it in writing for your specific facts. Any supplier who tells you the category is settled and simple is describing their sales process, not your legal exposure.

What Real Peptides does differently

Real Peptides operates its Wholesale Partner Program around documentation a buyer can check independently. Catalog compounds are produced to 99%+ HPLC purity and put through seven-panel batch testing, and the resulting certificates of analysis are publicly verifiable — meaning a prospective partner can pull up lab results before applying, rather than requesting them from a sales representative after a purchase. That ordering matters, because a COA you can only obtain post-sale cannot inform the buying decision it exists to support.

Fulfillment runs from the United States with a stated 5–7 day window, which shortens the planning gap between a reorder decision and restocked shelves. The Wholesale Partner Program uses a three-step application, so the qualification path is defined rather than discretionary, and pricing tiers are disclosed to approved partners instead of being reconstructed from quote to quote. Where much of the category treats testing data as a chargeable extra and pricing as a negotiation, the program's position is that both should be visible before a buyer commits inventory capital.

All compounds are supplied for research use only. They are not offered for human consumption, and no claim is made here about outcomes for any person.

Turning the checklist into a purchase order

If your business can answer the supplier questions above and has the receiving, storage and record-keeping practices to back them, the remaining step is qualification. Buyers building a research-compound catalog can apply to the Wholesale Partner Program at Real Peptides and review published batch documentation as part of that evaluation, then decide with the evidence in front of them rather than after the fact.

Buyers evaluating adjacent compounds can apply the same document-first standard across the catalog — reviewing lot data for signaling peptides such as KPV Peptide 10mg, tissue-signaling research items like BPC-157 10mg and TB-500 10mg, or the broader Gastrointestinal & Epithelial Research and Popular Peptides collections at Real Peptides.